PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
Commentary|Podcasts|May 30, 2025
How Recent Executive Orders Impact the Drug Pricing Landscape
Author(s)Nicholas Saraceno, Senior Editor
Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Advertisement
In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores:
- How recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies
- What life sciences companies should be doing now to proactively prepare for further executive action on drug pricing and market access
- The key differences in how executive policies versus legislative actions affect the pharma industry’s pricing and commercialization strategies
- The legal and strategic risks executive policy shifts pose to investors and biopharma leaders who may be planning product launches or portfolio expansion over the next few years
Advertisement
Related to this article
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
LogiPharma USA 2026: Data Readiness Must Come Before AI
2
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
3
Why PhRMA Sued to Block Medicare's GLOBE Pricing Model
4
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
5